| Cases | Controls |  |
---|---|---|---|
BLITZ population | |||
 Sex (m/f) | 38/19 | 1,978/2,521 |  |
 Mean age ± SD | 67 ± 7 | 62 ± 7 |  |
 Smoking (never/ever) | 25/32 | 2,313/2,175/11a |  |
 Stage (Tis/I/II/III/IV) | 4/19/6/19/3/6a | — |  |
Screening setting (plate A) | |||
 Study | BLITZ | BLITZ |  |
 Sex (m/f) | 30/16 | 29/17 |  |
 Mean age ± SD | 67 ± 7 | 67 ± 7 |  |
 Smoking (never/ever) | 21/25 | 25/21 |  |
 Stage (Tis/I/II/III/IV) | 2/15/5/16/3/6a | — |  |
  Cell proportions | |Δ| | ||
  Granulocytes | 54.9 ± 12.8 | 48.7 ± 14.9 | 6.2 |
  Monocytes | 7.2 ± 1.9 | 7.6 ± 2.8 | 0.4 |
  Natural killer cells | 11.7 ± 5.2 | 13.3 ± 5.8 | 1.7 |
  CD8+ T cells | 3.5 ± 4.1 | 4.4 ± 3.8 | 0.9 |
  CD4+ T cells | 16.7 ± 7.7 | 19.1 ± 9.5 | 2.3 |
  B lymphocytes | 5.9 ± 2.8 | 6.8 ± 3.9 | 0.9 |
(Difference in mean LC is not significant, p-value 0.29)c | |||
Clinical setting (plates B and C) | |||
 Study | DACHS+ | BLITZ |  |
 Sex (m/f) | 57/36 | 57/37 |  |
 Mean age ± SD | 65 ± 8 | 65 ± 8 |  |
 Smoking (never/ever) | 43/50 | 47/47 |  |
 Stage (Tis/I/II/III/IV) | 4/28/41/29/22/1a | — |  |
 Neoadj. therapy (none/rad./chemo./comb.)b | 60/12/2/19 | — |  |
  Cell proportions | |Δ| | ||
   Granulocytes | 64.9 ± 12.8 | 52.3 ± 12.6 | 12.6 |
   Monocytes | 9.3 ± 3.8 | 7.8 ± 2.7 | 1.5 |
   Natural killer cells | 7.2 ± 4.3 | 11.1 ± 5.2 | 3.9 |
   CD8+ T cells | 2.0 ± 2.9 | 3.5 ± 3.9 | 1.5 |
   CD4+ T cells | 12.6 ± 7.1 | 19.4 ± 7.8 | 6.9 |
   B lymphocytes | 4.0 ± 2.6 | 5.9 ± 2.9 | 1.9 |
(Difference in mean LC is significant, p-value 3.9 × 10−11)c |